BlackRock
ABOS icon

BlackRock’s Acumen Pharmaceuticals ABOS Stock Holding History

BlackRock’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Buy
2,490,115
+2,311,789
+1,296% +$5.71M ﹤0.01% 3839
2026
Q1 		$421K Buy
178,326
+8,821
+5% +$22.5K ﹤0.01% 4570
2025
Q4 		$358K Sell
169,505
-5,185
-3% -$10.3K ﹤0.01% 4574
2025
Q3 		$299K Sell
174,690
-117,267
-40% -$162K ﹤0.01% 4593
2025
Q2 		$339K Sell
291,957
-2,039,092
-87% -$2.19M ﹤0.01% 4532
2025
Q1 		$2.56M Sell
2,331,049
-40,998
-2% -$58.6K ﹤0.01% 3915
2024
Q4 		$4.08M Buy
2,372,047
+40,517
+2% +$97.6K ﹤0.01% 3810
2024
Q3 		$5.78M Buy
2,331,530
+172,869
+8% +$469K ﹤0.01% 3641
2024
Q2 		$5.22M Buy
2,158,661
+1,968,964
+1,038% +$6.27M ﹤0.01% 3668
2024
Q1 		$768K Sell
189,697
-58,398
-24% -$220K ﹤0.01% 4272
2023
Q4 		$953K Sell
248,095
-335,319
-57% -$995K ﹤0.01% 4275
2023
Q3 		$2.42M Buy
583,414
+100,090
+21% +$618K ﹤0.01% 3923
2023
Q2 		$2.32M Sell
483,324
-188,307
-28% -$902K ﹤0.01% 3988
2023
Q1 		$2.73M Sell
671,631
-473,056
-41% -$2.47M ﹤0.01% 3907
2022
Q4 		$6.18M Buy
1,144,687
+29,660
+3% +$199K ﹤0.01% 3630
2022
Q3 		$11.2M Sell
1,115,027
-1,578,284
-59% -$9.05M ﹤0.01% 3372
2022
Q2 		$12.7M Sell
2,693,311
-1,138,010
-30% -$4.28M ﹤0.01% 3380
2022
Q1 		$15M Buy
3,831,321
+721,651
+23% +$3.93M ﹤0.01% 3355
2021
Q4 		$21M Buy
3,109,670
+240,879
+8% +$2.65M ﹤0.01% 3243
2021
Q3 		$42.6M Buy
+2,868,791
New +$47.7M ﹤0.01% 2765

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

BlackRock's ABOS Position: Q2 2026 in Review

BlackRock increased its Acumen Pharmaceuticals (ABOS) stake by 1,296% in Q2 2026, buying an estimated $5.71M and bringing the position to 2,490,115 shares worth $6.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

BlackRock first reported a position in ABOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $42.6M in Q3 2021. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • BlackRock held 2,490,115 shares of Acumen Pharmaceuticals worth $6.65M as of Q2 2026.
  • BlackRock bought 2,311,789 Acumen Pharmaceuticals shares in Q2 2026, an estimated $5.71M.
  • Acumen Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3839 holding.
  • BlackRock first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • BlackRock's Acumen Pharmaceuticals position peaked at $42.6M in Q3 2021.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.